Constitutive DNase I Hypersensitivity of p53-Regulated Promoters*

Corey D. BraastadDagger , Zhiyong HanDagger , and Eric A. Hendrickson§

From the Dagger  Department of Molecular Biology, Cellular Biology and Biochemistry, Brown University, Providence, Rhode Island 02912 and § Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota Medical School, Minneapolis, Minnesota 55455

Received for publication, May 1, 2002, and in revised form, October 25, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The ability of p53 to alter, at the transcriptional level, the gene expression of downstream targets is critical for its role as a tumor suppressor. Most models of p53 activation postulate the stepwise recruitment by p53 of coactivators, histone acetyltransferases, and/or chromatin remodeling factors to a promoter region to facilitate the subsequent access of the general transcriptional machinery required for transcriptional induction. We demonstrate here, however, that the promoter regions for the p53 target genes, p21, 14-3-3sigma , and KARP-1, exist in a constitutively open conformation that is readily accessible to DNase I. This conformation was not altered by DNA damage or by whether p53 was present or absent in the cell. In contrast, p53 response elements, which resided outside the immediate promoter regions, existed within DNase I-resistant chromatin domains. Thus, p53 activation of downstream target genes occurs without p53 inducing chromatin alterations detectable by DNase I accessibility at either the promoter or the response element. As such, these data support models of p53 activation that do not require extensive chromatin alterations to support cognate gene expression.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The differential chromatin structure and nuclease accessibility at a promoter region has long been recognized as a key distinguishing feature between active and inactive genes (reviewed in Ref. 1). Almost invariably, the promoter regions of active genes are marked experimentally by hypersensitivity to restriction endonucleases (2, 3) or, more commonly, DNase I (4). Although this hypersensitivity can be caused by torsional or topological stress in the DNA and distortions in the chromatin structure resulting from transcription factor binding, it is generally caused by the absence of nucleosomes or their remodeling (1, 4). The paucity of nucleosomes, in turn, is a direct consequence of the repressive effect that nucleosomes have on the transcriptional machinery and the requirement to alleviate that effect for productive transcription to occur (5-7). Thus, inactive genes usually have promoters that are nucleosomal, are insensitive to DNase I, and are regarded as being in a closed confirmation whereas active genes usually have core promoters that are nucleosome-free, hypersensitive to DNase I, and in an open configuration. Consequently, one of the hallmarks of gene induction mechanisms is the remodeling of the nucleosomal architecture of a promoter as it is activated (5, 6, 8).

Enormous strides have been made in the last decade in understanding transcriptional activation at the chromatin level. In particular, the activation of expression of many, although not all (9-11), inducible eukaryotic genes is consistent with what can collectively be called recruitment models of gene activation (3, 7, 8) (reviewed in Ref. 12). These models usually require, in response to some extracellular cue, the induction of a specific transcription factor and the subsequent interaction of that factor with its cognate response element, which is invariably a cis-acting sequence located within the minimal promoter region of the relevant target genes. These transcription factors then recruit either chromatin remodeling factors (13, 14) or histone transacetylases (HATs1; reviewed in Ref. 15) or both, which catalyze the opening of the chromatin at the promoter. The subsequent (7) recruitment of additional coactivators, general transcription factors, and RNA polymerase II then facilitates gene expression. Implicit in all of these models is the assumption that chromatin alterations at the promoter will accompany and/or are required for gene induction (16, 17).

Although the signal transduction pathways responsible for the cellular response(s) to genotoxic stress are complex (reviewed in Refs. 18 and 19), it has become apparent that the p53 tumor suppressor lies at the heart of the matter. In particular, p53 suppresses tumorigenic growth by transcriptionally inducing genes that facilitate either survival or death of an injured cell (reviewed in Refs. 20-22). Active p53 binds, albeit with varying affinities (23), to consensus response elements (p53 REs) within genetic regulatory loci. p53 REs consist of tandem palindromic decamers of 5'-PuPuPuC(A/T)(A/T)GPyPyPy-3' (where Pu represents purine and Py represents pyrimidine) (24). Binding of p53 to p53 REs alters the expression of a host of genes (reviewed in Ref. 25), which fall into five main categories and include genes 1) that act to arrest the cell cycle at G1/S and G2, 2) that are involved in the induction of the G2/M cell cycle checkpoint, 3) that are involved in DNA repair, 4) that play roles in the induction or suppression (26) of apoptosis, and 5) that are involved in autoregulation (20-22).

p53 is normally expressed at very low steady-state levels, because it is rapidly turned over via proteosome-mediated degradation. This degradation requires the specific MDM2-mediated ubiquitination of p53 (27, 28). The disruption of the inhibitory interaction between MDM2 and p53, which can occur by phosphorylation of either MDM2 (29, 30) or p53 (reviewed in Refs. 21 and 31), permits the opportunistic access of HAT complexes to the N terminus of p53. Binding of HATs to p53 results in acetylation of the C-terminal regulatory domain of p53, which strongly activates the latent specific DNA binding activity of p53 in vitro (32). The biological consequences of p53 acetylation in vivo, however, are less clear, and it has been argued that at least one important aspect of p53-HAT interactions may rather be the ability of p53 to facilitate the delivery of the HATs to the adjacent p53-inducible promoters (33, 34) (reviewed in Ref. 35). Indeed, the association of p53 with HATs suggests that modulation of the promoter chromatin structure may be essential for the activation of p53-responsive genes (33, 34). Thus, implicit in many models of p53 activation is the assumption that alteration or remodeling of the nucleosomal architecture of a promoter is likely to be a critical feature of the mechanism of gene activation.

We have experimentally begun to address the question of how p53 influences the chromatin structure of promoters and p53 REs of p53 target genes. Here we demonstrate that the chromatin at three separate target promoter elements was constitutively open and accessible to DNase I, regardless of whether gene expression was induced and/or whether p53 was present. In contrast, the chromatin domains of p53 REs were closed and were not altered following genotoxic stress or by p53 binding. These experiments demonstrate that p53 activation of gene expression does not require extensive chromatin alterations at either the RE or the promoter of the target gene.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cells-- A set of matched p53+/+ and p53-/- HCT116 cell lines (36, 37) were generously provided to us by Dr. Bert Vogelstein (Johns Hopkins University). All cells were cultured in McCoy's 5A medium supplemented with 100 µg/ml penicillin and streptomycin, and 2 mM L-glutamine at 37 °C with 5% CO2.

RT-PCR-- RT-PCR was performed essentially as described (38). Total RNA was isolated from p53+/+ and p53-/- HCT116 cells at 0, 2, 4, and 6 h post-IR (10 Gy) treatment via the TRIzol (Invitrogen) protocol. 5 µg of total RNA was further purified with the DNA-Free RNA kit (Zymo Research; Orange, CA), assayed for the presence of contaminating genomic DNA, and then used in downstream protocols. cDNA synthesis reactions were performed via random hexamer priming with SuperScriptTM (Invitrogen) reverse transcriptase (for p21, 14-3-3sigma , and beta -actin) or via gene-specific priming with ThermoScriptTM (Invitrogen) thermostable reverse transcriptase at 55 °C (for KARP-1, 5'-CTTATTCCCCGACCGCACCATGTTGCCGGT-3'). The cDNA from each sample was then subjected to one round of PCR amplification consisting of an initial melting step (94 °C for 5 min) followed by a number, optimized for each amplicon, of repetitive cycles consisting of denaturation at 94 °C for 30 s, annealing at 55 °C for 1 min, and extension at 72 °C for 30 s using primers (see below) specific to different exons within p21, 14-3-3sigma , KARP-1, and beta -actin (the latter to control for quantification of cDNA pools) messages. 26 PCR cycles were utilized for p21 and 14-3-3sigma , 30 for KARP-1, and 24 for the beta -actin control.

Chromatin Immunoprecipitations-- Modifications of the published method (39) included harvesting in phosphate-buffered saline solution, pH 7.6, and cross-linking with 2% formaldehyde. Cross-linking was quenched by addition of 125 mM glycine for 5 min followed by two ice-cold washes with phosphate-buffered saline. Cells were permeabilized in lysis buffer (50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate/protease inhibitors) and kept on ice. Chromatin was sheared by sonication until the DNA was an average length of 600-1000 bp as assessed by agarose gel electrophoresis. Cellular debris was removed by centrifugation for 5 min at 13,000 rpm and then the supernatant was centrifuged again for 15 min. A 1/20 aliquot of the cleared extract was reserved as an input control for PCR reactions, and the remaining extract was incubated overnight with antibodies at 4 °C on a rotator. 50 µl of a protein A-Sepharose slurry was added and incubated for 1.5 h at 4 °C while rotating and then the Sepharose beads were pelleted by centrifugation. The beads were then washed at room temperature twice with lysis buffer, once with lysis buffer containing 500 mM NaCl, once with wash buffer (10 mM Tris-HCl, pH 8.0, 250 mM LiCl, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM EDTA), and once with 10 mM Tris-HCl, pH 8.0, 1 mM EDTA. Beads were resuspended in 200 µl of elution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA), and precipitated protein-DNA complexes were eluted from the antibodies/beads by incubation at 65 °C for 30 min. The resulting supernatants, along with input aliquots, were subjected to cross-link reversal by heating to 65 °C overnight followed by treatment with 100 µg of proteinase K for 2 h at 37 °C. DNA was purified by phenol/chloroform extraction followed by addition of 2 µg of glycogen carrier for EtOH precipitation with a 1/10 volume of 3 M sodium acetate. Precipitated DNA was resuspended in 100 µl of water, and 1/50 of the immunoprecipitates or 1/10,000 of the input were used as templates in PCR reactions with locus-specific primers.

DNase I Hypersensitivity Assays-- The basic protocol has been described (40), and all preparatory steps were carried out at 4 °C. Briefly, 1.5 to 2 × 108 trypsinized cells were centrifuged at 2000 rpm for 10 min. The cells were washed twice by resuspension in 25 mM Mg2+/Ca2+-free phosphate-buffered saline and centrifugation at 1500 rpm for 10 min. The cells were then resuspended in freshly made douncing buffer (20 mM Tris-HCl, pH 7.4, 3 mM CaCl2, 2 mM MgCl2, 0.3% Nonidet P-40) and transferred to a Dounce homogenizer. Following incubation on ice for 10 min and removal of an aliquot to quantitate cellular breakage, cells were broken apart with ~ 6 hard strokes and checked by visual observation under a microscope. Following quantitative breakage, nuclei were isolated by centrifugation at 900 rpm for 7 min. Nuclei were washed twice in 25 ml of resuspension buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2) followed by centrifugation at 900 rpm for 7 min. Nuclei were then resuspended in 1 ml of resuspension buffer, and a 25-µl aliquot was diluted into 475 µl of 1% SDS for an A260 measurement. The nuclear stock was diluted with resuspension buffer until the A260 of the 1:20 dilution equaled 0.5. A quenched nuclei sample was removed and added directly to cell lysis solution (Gentra Systems, Minneapolis, MN). The purified, diluted nuclei were divided into untreated and treated aliquots and warmed to 37 °C. For the untreated aliquot, an endogenous DNase I activity sample was collected at 5 min and added to cell lysis solution. For the treated aliquot, RQDNase I (~1 µg/5 µl; Clontech) was added to a final concentration of 1 µg/ml of nuclei. Aliquots of the treated nuclei were removed at 30 s, 2 min, and 5 min and added to cell lysis solution and mixed well. Genomic DNA was isolated from each sample as described in the DNA isolation kit (Gentra Systems, Minneapolis, MN) protocol (scaled up based on cell number) and then resuspended in DNA hydration solution (10 mM Tris-HCl, pH 8.0) at 0.5 µg/µl. Genomic DNA was then analyzed by Southern blotting to detect hypersensitive sites at particular loci.

Southern Blots-- All blots were performed with 10 µg of genomic DNA/lane in 0.6 to 2.0% agarose gels following treatment with the appropriate restriction enzyme(s) as shown in each figure legend. Double digestions were performed simultaneously. Following electrophoresis, agarose gels were transferred to nitrocellulose membranes as described (41). Hybridizations were performed according to the PerfectHyb Plus protocol (Sigma) with a 5-min prehybridization at 64 °C with sheared salmon sperm DNA followed by the addition of 32P radiolabeled probe prepared via the random hexamer Klenow synthesis Prime-It II protocol (Stratagene) and subsequently purified over a G-50 Sephadex column. Following overnight hybridizations, the blots were washed twice at room temperature with 2× SSC for 5 min, twice (once at room temperature, once at 64 °C) with 1× SSC for 10 to 20 min, and two to four times at 64 °C with 0.1× SSC. The exposure of the blots to Eastman Kodak Co. autoradiographic film at -80 °C in the presence of an intensifying screen varied from 1 h to 3 days.

Antibodies, Primer Sequences, and Southern and Northern Blot Probes-- Antibodies used in chromatin immunoprecipitation analysis included phosphoserine 15-p53 (Cell Signaling Technology, Beverley, MA) and Ab421 and p21/WAF1 (Calbiochem) antibodies. The PCR primers used for the chromatin immunoprecipitation assays were as follows. For the KARP-1-responsive element: KP-ChIP-9, 5'-AAGATGAGGAAGAGATGGGG-3' and KP-ChIP-10, 5'-TGAGTCAGAAGTGTGAGAGTG-3'; for the p21/WAF1-responsive element: WAF-ChIP-1, 5'-TCCACCTTTCACCATTCCC-3' and WAF-ChIP-2, 5'-ATAACTTCTA GCTCACCACCAC-3'; and for the 14-3-3sigma -responsive element: 1433-ChIP-1, 5'-AAAATCACTCACTCTCACTACCTC-3' and 1433-ChIP-2, 5'-TTCCTGCTTATCTGCCCCAC-3'. The KARP-1 primers generate a 200-bp fragment located 380 bp distal from the RE. The p21 and the 14-3-3 primers generate 586- and 368-bp fragments that span their respective REs.

DNase I hypersensitivity assay Southern blot probes were generated as follows. For p21/WAF1: the primers WAF1-1, 5'-TCCTCACATCCTCCTTCTTC-3' and WAF1-2, 5'-CGCTCCTATACATCCAAACC-3' were used in a PCR reaction to make an 882-bp product; for 14-3-3sigma , the primers 1433-1, 5'-TGTGTAGTGCCAGGTGAAG-3' and 1433-5, 5'-AAGGTGGAGGGGACAAAGAG-3' were used to make a 1216-bp product. The probe used to detect the KARP-1 promoter locus was a XmaI-BglII 1064-bp restriction derived from an 1812-bp ScaI GenomeWalker (Clontech) product generated with the primers K63-3, 5'-TCTTGACACCCGAACTAAAAACTTGAC-3' and K63-4, 5'-CTCCCTGCTCTGCCTCTCATTATTC-3'.

The PCR primers used for the RT-PCR reactions were as follows: for p21, 5'-ACTGTGATGCGCTAATGGC-3' and 5'-ATGGTCTTCCTCTGCTGTCC-3'; for 14-3-3sigma , 5'-GTCTGATCCAGAAGGCCAAG-3' and 5'-CTCCTCGTTGCTTTTCTGCT-3'; for KARP-1, 5'-CGTACAAGAAGGGAGACAAGGACCACTGAC-3' and 5'-CTTATTCCCCGACCGCACCATGTTGCCGGT-3'; and for beta -actin, 5'-ATCTGGCACCACACCTTCTACAATGAGCTGCG-3' and 5'-CGTCATACTCCTGCTTGCTGATCCACATCTGC-3'.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

IR-induced Up-regulation of p21, 14-3-3sigma , and KARP-1 Gene Expression in Wild-type, but Not p53-Null, HCT116 Cells-- HCT116 is an immortalized human colon cancer cell line that is diploid, contains wild-type p53 and p21 genes, and responds normally to DNA damaging agents with respect to the induction of p53 and cell cycle arrest (36, 37, 42). RT-PCR analysis was used to characterize the induction of mRNA for three p53-responsive genes in HCT116 cells exposed to 10 Gy of IR. The genes investigated were p21 and 14-3-3sigma , which are involved in the DNA damage-inducible G1 and G2 checkpoints, respectively (reviewed in Ref. 25), and KARP-1, a DNA damage-inducible isoform of the Ku86 DNA repair gene (41, 43). beta -Actin mRNA expression was used to control for the quality of the cDNA pools. In contrast to beta -actin, the p21, 14-3-3sigma , and KARP-1 mRNAs were expressed at low levels (Fig. 1A, lane 0) (data not shown) in normally cycling cells. Upon exposure to X-irradiation, the message levels for all three genes rose sharply in contrast to beta -actin expression, which remained essentially unchanged (Fig. 1A). An isogenic HCT116 cell line in which the p53 gene had been inactivated via somatic gene targeting (p53-/- cells) (36, 37) had very low or non-detectable resting state levels of p21, 14-3-3sigma , and KARP-1 mRNAs, and no induction of any of the genes was observed following IR exposure (Fig. 1B). This analysis revealed the expected profiles of induction, and the previously demonstrated dependence upon p53, for these well characterized p53-inducible genes.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 1.   p53-responsive mRNAs are up-regulated in HCT116 cells following IR exposure. A, wild-type HCT116 p53+/+ cells were exposed to 10 Gy of gamma -radiation. At the indicated time (in h), mRNA was isolated from the cells and used for RT-PCR using primers specific for the indicated genes. RT-PCR using beta -actin-specific primers was performed to ensure the quality of the mRNA preparations. B, the same experiment as described for A was carried out except that mRNA isolated from HCT116 p53-/- cells was utilized.

The Promoters, but Not the p53 REs, for p21, 14-3-3sigma , and KARP-1 Are Hypersensitive to DNase I-- The putative promoter regions for p21 (reviewed in Ref. 44), 14-3-3sigma (45-48), and KARP-1 (41) have been identified. These promoters correspond to CpG-rich domains to which the likely start site of transcription (+1) has been mapped (Fig. 2). Multiple putative p53 REs reside within the vicinity of these promoters, and those REs that have been defined functionally as responsive are indicated (Fig. 2). To investigate the chromatin structure of these p53-inducible genes, we utilized DNase I hypersensitivity assays (reviewed in Refs. 4 and 49). In this technique, Southern blot analysis reveals the presence or absence of a region of chromatin that is relatively open, and therefore accessible, to the endonuclease DNase I. Nuclei, prepared from wild-type HCT116 cells that had been mock treated or X-irradiated (10 Gy), were harvested and mixed with DNase I for 0.5, 2, or 5 min. Genomic DNA was then purified, subjected to the indicated restriction enzyme cleavage(s), and analyzed by Southern blotting. Probes specific to each locus (Fig. 2) were used to detect changes in the restriction enzyme cleavage patterns of DNA isolated from irradiated versus non-irradiated cells at the varying durations of endonuclease treatment. In the absence of DNA damage, the promoter regions of p21, 14-3-3sigma , and KARP-1 were already hypersensitive to DNase I indicating a relatively open (i.e. non-nucleosomal) chromatin structure (see Figs. 2 and 3, Non-IR). In every case, the major DNase I hypersensitive site (DHS) detected resided immediately adjacent to the transcriptional start site (+1; see Fig. 2). For p21, a second strong DHS was also detected 2 kb downstream of the transcriptional start site within intron 1 (Fig. 3, EcoRI + EcoRV digest; see also Fig. 5), but this site was not characterized further. A distinct lack of DHSs was observed at all of the p53 REs save for a few weak DHSs flanking the p53 RE in the 14-3-3sigma locus (Figs. 2 and 3, Non-IR) (data not shown). To see whether the chromatin structure of these genes was altered upon DNA damage, cells were exposed to IR (10 Gy), nuclei were isolated, and DNase I hypersensitivity assays were performed again. Although the intensities of the DHSs varied somewhat from experiment to experiment, the only consistent salient difference detected between the irradiated and non-irradiated samples was that the irradiated samples were unexpectedly more resistant to nuclease digestion (Fig. 3, compare 2' of DNase I Treatment lanes for IR with Non-IR). This trait, which is poorly understood (see "Discussion") was not characterized further. Most importantly, no extra IR-inducible DHSs were ever observed. From these experiments we concluded that the promoter regions for p21, 14-3-3sigma , and KARP-1 were constitutively open to DNase I. In addition, we concluded that none of the p53 REs were DNase I hypersensitive and that this attribute did not change immediately following X-irradiation.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   Cartoons of the genomic loci of the three p53-responsive genes studied. The genomic DNA is depicted as a dark line. The starts of transcription are indicated as +1. The thick vertical arrows correspond to the location of the major DHS at each locus (see e.g. Fig. 3). Thinner vertical arrows represent the weaker DHSs, with the thickness of the arrow approximating the intensity of the DHS. The promoter regions are embedded within CpG islands, which are designated by rightward-hatched rectangles below the dark line. The areas utilized as probes for the DHS assays are shown as leftward-hatched rectangles under the dark line. Relevant restriction enzyme sites are shown as dashed vertical lines, and the distances between these sites is shown with the thin lines. Exons are represented as shaded rectangles. The p53 REs are shown as small ovals. Shaded ovals (responsive) correspond to REs that are required for transactivation and/or have been shown to bind p53. In the case of p21, two REs have been identified, and these are designated as distal and proximal based upon their proximity to the start of transcription. Blackened ovals (non-responsive) correspond to REs that are a good match for the p53 consensus sequence but that do not appear to be involved in either transactivation or p53 binding. The p53 REs are also characterized by their homology to the 10-bp consensus sequence; e.g. 10/10(0)8/10 indicates an RE that consists of 10 nucleotides that are a perfect match separated by 0 nucleotides from 10 nucleotides in which only 8 matches exist.


View larger version (56K):
[in this window]
[in a new window]
 
Fig. 3.   An open chromatin structure which is independent of DNA damage exists over the promoters, but not the p53 REs, of p21, 14-3-3sigma , and KARP-1 genes. HCT116 cells were either left untreated (Non-IR) or X-irradiated (IR; 10 Gy) and then nuclei were isolated from the cells as described under "Experimental Procedures." These nuclei were exposed to DNase I for 30 s (30"), 2 min (2'), or 5 min (5') and then genomic DNA was isolated, restricted with the appropriate restriction enzyme(s) (shown on the left), and subjected to Southern blot analysis using the probes indicated in Fig. 2. Sites hypersensitive to DNase I are indicated with arrows. The thickness of the arrow corresponds approximately to the intensity of the DHS. An identical analysis for genomic DNA isolated from cells not treated with DNase I is shown on the far left of the top blot (Ctrl gDNA). In addition, the positions (in kb) of the molecular markers used for these gels are indicated on left side of each autoradiogram. The approximate locations of the relevant promoter elements for each of the loci are shown on the far right. p, proximal; d, distal.

The DNase I Hypersensitivity Profiles of p53 Target Gene Promoters Is Not Altered Following X-irradiation-- To investigate whether alteration of the chromatin structure of the p53 target gene promoters required a lag or maturation phase, HCT116 cells were X-irradiated (10 Gy) and then DHS assays were carried out on cells isolated at varying times post-irradiation. The DNase I hypersensitivity profiles at 15 min, 30 min, 1 h, or 1.5 h post-irradiation were indistinguishable from cells that were analyzed immediately following X-irradiation (Fig. 4) with the exception that once again IR-treated samples were invariably somewhat more resistant to DNase I digestion than non-IR samples (compare 0' lanes with 15'; see Fig. 4). Importantly, however, even as transcription for these genes rose over 5-fold (Fig. 1), there was no corresponding detectable alteration of the chromatin structure of the promoters or the p53 REs.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 4.   The DNase I sensitivity profiles of the p21, 14-3-3sigma , and KARP-1 promoters and p53 REs do not change over time. A DHS assay as described for Fig. 3 was carried out except that the cells were harvested, and nuclei were prepared at the times indicated post-exposure to IR (10 Gy). All prepared nuclei were subjected to a 5-min DNase I treatment.

The Absence of p53 Does Not Alter the DNase I Hypersensitivity of the p21, 14-3-3sigma , or KARP-1 Promoters-- In the absence of p53, non-detectable levels of p53 target genes were expressed in cells exposed to IR (Fig. 1). Thus, to extend these studies, the chromatin structure of p53-inducible promoters was investigated in HCT116 p53-null cells, where the p53 alleles have been inactivated by two rounds of gene targeting (36, 37). The DNase I hypersensitivity patterns of p21, 14-3-3sigma , and KARP-1 loci in p53-/- cells were indistinguishable from those observed in wild-type cells with the exception of the two weak DHSs at the 14-3-3sigma locus, which could not reproducibly be detected in p53-null cells (compare Fig. 5 with Fig. 3). Moreover, like in wild-type cells, the hypersensitivity pattern was not altered upon X-irradiation (Fig. 5, compare Non-IR with IR). Thus, despite a complete lack of detectable basal transcription of these genes in p53-null cells, the discrete hypersensitive regions of the respective promoters were present and indistinguishable from that of wild-type cells.


View larger version (74K):
[in this window]
[in a new window]
 
Fig. 5.   The absence of p53 does not affect the gross chromatin structure of any of the p53-responsive genes studied. HCT116 p53-/- cells were analyzed for DHSs exactly as described for wild-type cells in Fig. 3. All symbols are as in Fig. 3.

p53 Binding to Its REs Following X-irradiation Is Detectable by ChIP-- The absence of chromatin alterations at p53 REs as detectable by DNase I accessibility compelled us to assess p53 interactions with its cognate binding sites by other techniques. Thus, chromatin immunoprecipitation (ChIP; reviewed in Ref. 50) was utilized to analyze the in vivo occupancy of p53 REs. Preparations of nuclei from either mock or IR-treated wild-type or p53-null HCT116 cells were cross-linked with 2% formaldehyde and subjected to sonication to disrupt chromatin into ~600- to 1,000-bp pieces. Subsequently, p53-DNA complexes were immunoprecipitated, the cross-links were reversed, and the DNA was purified and then subjected to PCR analysis for the enrichment of a particular genomic locus. To ascertain whether a particular subset of modified p53 was associated with p53 REs we carried out the ChIP experiments using monoclonal antibodies specific for phosphoserine 15 p53 or by using monoclonal Ab421, which is known to stabilize the binding of p53 to DNA (51). The amount of phosphoserine 15 p53 associated with these p53 REs was initially low in untreated cells, and it increased ~4- to 10-fold in every case following IR exposure (Fig. 6). Similarly, the monoclonal Ab421 detected an increase in p53 occupancy at these sites following X-irradiation (Fig. 6), consistent with what has been reported (23, 51). In all cases, no or very low levels of p53 were detected in p53-null cells or when an irrelevant antibody (p21) was utilized (Fig. 6). From these experiments we concluded that p53 was indeed binding to its REs in a DNA damage-inducible manner even though this event was not accompanied by DNase I hypersensitivity.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 6.   p53 interacts with p53 REs in DNA-damaged HCT116 cells. Wild-type (+ p53 status) and p53-/- (- p53 status) HCT116 cells were either X-irradiated (10 Gy; +IR) or mock treated (-IR). 30 min later the cells were harvested, and ChIP analysis was carried out using either monoclonal Ab421 or an epitope-specific monoclonal Ab to activated p53 (phosphoserine 15 p53). After reversal of the protein cross-links and DNA purification, a PCR analysis for each of the indicated loci was carried out with locus-specific primers. For p21, only the distal RE was analyzed. Enrichment of the p53 RE in the immunoprecipitated DNA pool indicates the interaction of p53 with the RE. PCR amplification with primers for 14-3-3sigma was carried out for more cycles than the other loci, indicating less enrichment for this locus in the immunoprecipitation pool. Control input PCR reactions are shown on the far left. These samples correspond to 1/300 of the reaction volume utilized for the ChIPs.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study we have established that the chromatin structures of the promoters for three p53-inducible genes were accessible to DNase I in human HCT116 cells growing under normal conditions and regardless of whether the cells were damaged or p53 was present. We have demonstrated that the binding of p53 to its cognate REs in response to DNA damage occurs in the absence of detectable chromatin alterations at the RE. These data confirm and significantly extend the previous observations that the Mdm2 (52) and GADD45 (10) promoters, which are both dependent upon p53 for DNA damage-inducible gene expression, are constitutively nucleosome-free and DNase I hypersensitive. This study has important implications for the mechanism of p53 transactivation.

Significance of DHSs at p53-regulated Promoters under Non-inducing Conditions-- Empirically, it has long been recognized that the promoters of genes that are being actively transcribed are hypersensitive to DNase I, usually because of the absence of nucleosomes (reviewed in Refs. 1 and 4). For example, the hypoxanthine phosphoribosyltransferase gene is X-linked. On the active X chromosome, where the gene is transcribed, the promoter is nucleosome-free (6) and is hypersensitive to DNase I (6, 53). In contrast, the hypoxanthine phosphoribosyltransferase gene on the inactive X chromosome is not transcribed, and its promoter is occupied by nucleosomes, and it is not DNase I hypersensitive. Reactivation of the inactive allele by azadeoxycytidine is accompanied by the appearance of hypoxanthine phosphoribosyltransferase mRNA and the DHS (54). Similarly, beta -globin transcription is dependent upon the erythroid Krueppel-like factor (EKLF) transcription factor. Cells lacking EKLF do not produce globin transcripts and do not exhibit a DHS at the proximal beta -globin promoter (55, 56). Restoration of EKLF to EKLF-null cells results in the reappearance of the DHS and of globin transcription (8). These and similar studies, coupled with the observation that the degree of DNase I hypersensitivity often correlates with nucleosome remodeling (57), demonstrate that the appearance of a DHS at a promoter usually implies that the core promoter is nucleosome-free and that the gene is being transcribed. Because the promoters for p21, 14-3-3sigma , and KARP-1 contain constitutive DHSs even before the genes are induced (Fig. 3) a logical interpretation of this observation is that these promoters are nucleosome-free and that the genes are being expressed in the absence of DNA damage (Fig. 7B). Whether the p21, 14-3-3sigma , and KARP-1 gene promoters are truly nucleosome-free and where the nucleosome-free boundaries reside will require additional MNase footprinting studies, although these data are completely consistent with the prior demonstration that the Mdm2 (52) and GADD45 (10) promoters are constitutively hypersensitive to DNase I and that positioned nucleosomes flank the GADD45 promoter, which itself is nucleosome-free (10). Taken together, these studies suggest that the vast majority of, if not all, p53-dependent DNA damage-inducible promoters reside in open chromatin. Moreover, the openness of these promoters is consistent with the genes being transcribed at low, basal levels in non-damaged wild-type cells (Fig. 1) (data not shown). It should be noted, however, that the basal expression of p21, 14-3-3sigma , and KARP-1 in p53-null cells was greatly reduced over that observed in wild-type cells such that the transcripts could no longer be detected by Northern blotting (data not shown). It is unlikely that expression is reduced to zero, however, as the expression of p21, albeit at significantly reduced rates, has been reported in a p53-null cell line (33). Together, these data imply that although p53 is not essential for the basal transcription of these genes, its presence enhances constitutive expression. This conclusion is consistent with a study in which a temperature-sensitive p53 protein was shown to induce transcription of the Mdm2 gene in the absence of DNA damage only under permissive conditions (52). Whether p53 enhances basal transcription via the same mechanism that it uses to augment transcription following DNA damage (see below) is a subject that deserves more study.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 7.   Models for transactivation of p53-regulated genes. A, canonical recruitment model of transactivation. A target gene is diagrammed in a closed conformation with nucleosomes (flesh-colored ovals) occluding the p53 RE (yellow square) and the transcription initiation site (blue TATA rectangle and arrow). Following DNA damage, p53 is activated and binds to its RE. It then recruits HATs (green hexagon) or chromatin remodeling complexes (CRCs; orange circle), which open the chromatin occluding the promoter. p53 may then facilitate the additional recruitment of RNA polymerase II and general transcription factors (GTFs; pink oval). Transcriptional activation then occurs, which may be facilitated by additional coactivators, resulting in high levels of transcription (wavy green lines). B, simple activation model. All symbols are as in A. p53 target gene promoters are open, and low levels of constitutive transcription occur. Following DNA damage, activated p53 binds to its RE in the context of nucleosomal DNA. p53 then induces high levels of transcription potentially with the help of additional coactivators. C, paused polymerase model. All symbols are as in A. p53 target gene promoters are open and occupied by a paused RNA polymerase II. Following DNA damage, activated p53 binds to its RE in the context of nucleosomal DNA. p53 then induces high levels of transcription by inducing re-initiation of transcription.

Importance of DHSs at p53-regulated Promoters under Inducing Conditions-- In higher eukaryotes, chromatin is the physiological template for transcription. The functional effect of nucleosomes on transcription initiation is generally repressive, and the ability to overcome these inhibitory effects is invariably required for transcription to occur (reviewed in Refs. 1, 4, and 12). More often than not, transcription factors accomplish this task not through intrinsic enzymatic activities but through association with coactivators, HATs, and chromatin remodeling complexes (1). This mechanism of transcriptional activation is often referred to as "recruitment," and a vast amount of data has demonstrated that recruitment is actively utilized at a number of well characterized yeast promoters and eukaryotic viral promoters (16, 17) (reviewed in Refs. 12, 58, and 59). The documented association of p53 with HATs has led to the hypothesis that p53 similarly activates transcription by recruitment of factors that will facilitate chromatin opening at promoters (33, 34) (Fig. 7A).

In this study, however, we have demonstrated that although p53 is clearly essential for the induction of these genes following IR exposure (Fig. 1) (reviewed in Refs. 20-22), it does so without grossly altering the chromatin structure of the promoters that it transactivates (Fig. 3). These observations are virtually identical to those reported for the GADD45 promoter following IR exposure (10). Although our data cannot rule out subtle chromatin alterations at p21 and related p53-regulated promoters, they clearly do not support the contention that significant chromatin alteration is needed for p53-mediated gene activation. Indeed, the only reproducible alteration observed following X-irradiation was an increased resistance to DNase I immediately after irradiation (see Figs. 3 and 4). The mechanistic basis for this increased resistance is unknown. One possibility is that the exposure of cells to IR and general radioresistance have been correlated with the phosphorylation of the histones H2AX (60) and H3 (61), respectively. Histone phosphorylation, in turn, has long been associated with chromatin condensation, which would be consistent with the observed reduction in nuclease accessibility. Importantly, however, no other significant alterations in the DHS profile at the promoter were observed following X-irradiation (see Figs. 3 and 4) even over a time interval when p21, 14-3-3sigma , and KARP-1 transcription was known to be induced manyfold (Fig. 1).

If the association of HATs with p53 is not required for promoter opening, then HATs are presumably assisting transactivation through another mechanism. One possibility would be through their ability to act as factor acetyltransferases (reviewed in Ref. 15) and activate either p53 (62-64) or associated cofactors. Thus, our data are most consistent with a basic activation model in which, in their uninduced state, p53 target gene promoters are open, and the genes are being transcribed at a low level (Fig. 7B). Following DNA damage, p53 is activated and induces transcription either through the recruitment or stimulation of coactivators (33), including HATs, general transcription factors, or RNA polymerase II without, however, concomitant chromatin alterations (Fig. 7B).

Importance of DHSs at p53-regulated Promoters in p53-null Cells-- The open chromatin structure of p53 target genes was remarkably independent of p53 expression (Fig. 5). Although unexpected, there is precedent for the lack of a requirement for a transactivator in determining the chromatin structure of the target promoters. For example, major histocompatibility complex class II genes can be induced in a retinoblastoma tumor suppressor protein-dependent fashion (65, 66). In retinoblastoma-/- cells these genes are not induced although the promoter region is constitutively open as defined by DNase I hypersensitivity (67). Similarly, heat shock genes are highly induced following exposure to elevated temperatures. The promoters for these genes, however, are constitutively open and accessible to DNase I even in the absence of the transactivator, heat shock factor (reviewed in Ref. 68). In both of these cases the open architecture of the relevant promoters is established by a second transcription factor, whose expression precedes the expression of the transactivator. Thus, regulatory factor X is responsible for establishing the DHS at the HLA-DRA promoter (69) whereas GAGA factor performs the same role at heat shock gene promoters (70, 71). A logical extension of these observations is that there may be a transcription factor that binds to p53-regulated promoters and establishes the open chromatin confirmation prior to p53 activation. The identity of this putative transcription factor is unknown. The p21 promoter has been analyzed exhaustively, and a plethora of transcription factors have been implicated in its expression (reviewed in Ref. 44). Unfortunately, much less is known about the promoters for 14-3-3sigma and KARP-1 (41), and so a direct comparison of potential common cis-acting binding sequences is not possible at this time. It is interesting to note, however, that all three of these promoters coincide within CpG islands (Fig. 2). CpG islands are frequently rich in Sp1 or Sp1-like binding sequences (e.g. GGGCGG). Moreover, Sp1 family members are known to interact with the HATs, p300, and cAMP-response element-binding protein-binding protein (44), and it is tempting to speculate that these HATs cooperate with Sp1 to establish the constitutive open chromatin structures observed at p53-regulated promoters.

The constitutive open chromatin structure of p53-regulated genes also suggests an alternative mechanism of transactivation. In the case of heat shock genes (9, 72) (reviewed in Ref. 68), c-fos (73), and c-myc (74, 75) activation is regulated by promoter proximal pausing. For these genes, the chromatin structure of the promoters is constitutively open and contains an engaged RNA polymerase II, which is paused during elongation just downstream of the initiation site. The subsequent binding of the relevant transactivator then promotes rapid reinitiation of the stalled polymerase (Fig. 7C) (11). Clearly, the chromatin structure of the p21, 14-3-3sigma , and KARP-1 genes is strikingly similar to the chromatin structure of the heat shock, c-fos, and c-myc genes. Moreover, the genes regulated by promoter proximal pausing and p53 are genes that need to be induced in a rapid fashion in response to a variety of cellular stresses and conditions. Given that, at least in vitro, the assembly of the core transcriptional machinery takes several min, whereas the transition from initiation to elongation occurs within seconds (76), it is logical that these stress-related genes might be regulated similarly. There are, however, some subtle differences between p53-regulated genes and the genes regulated by promoter proximal pausing. In the case of the promoter pausing, even though a large nucleosome-free region exists over the proximal promoter region, the subsequent initiation of transcription results in downstream nucleosomal remodeling, which can be detected as additional nuclease hypersensitivity (11) (reviewed in Ref. 68). In the case of p53-regulated genes, no additional DHSs were detected (Fig. 3) even when transcription had increased manyfold (Fig. 1). Moreover, a strong argument has been made that the open chromatin region of genes regulated by promoter proximal pausing has evolved specifically to allow for a very rapid entry of the transactivator, whose cis-acting RE invariably resides within the promoter region. For p53-regulated genes, this is clearly not the case as many p53 REs can and do reside kilobases away from the promoter and the nuclease hypersensitive region (Fig. 2) (reviewed in Ref. 25). These differences notwithstanding, it will be important to determine whether the p21, 14-3-3sigma , and KARP-1 promoters are regulated by promoter proximal pausing (Fig. 7C).

Importance of the Lack of DHSs at p53 REs-- A second important finding of these studies was the lack of chromatin alteration (see Figs. 2-4) associated with p53 binding to its cognate REs (Fig. 6). In all four cases examined, the REs appeared to contain a chromatin structure that was inaccessible to DNase I, both before and after p53 binding. Most transcription factors are deleteriously affected, often by factors of 1000 or more, in their binding to nucleosomal templates as compared with naked DNA (77, 78). Thus, p53 appears to belong to a more restricted set of transactivators that are capable of binding to their cognate recognition sites within the context of nucleosomal DNA (reviewed in Refs. 79 and 80). Interestingly, however, in many of these latter cases the binding of the transcription factor to the DNA-nucleosome complex resulted in weakened DNA-nucleosome interactions that could be detected as increased nuclease sensitivity (81, 82). In the case of p53, no additional DHSs were detected after X-irradiation suggesting that either DNase I accessibility was not sensitive enough to detect these changes, for which there is precedent (83), or that p53 binding was occurring in the absence of significant nucleosomal alterations (10, 52). Our conclusion that p53 is capable of binding in the context of nucleosomal DNA is consistent with the recent observation that in vitro p53 binds preferentially to nucleosomal DNA (34). The ability of a transcription factor to bind to nucleosomes can be facilitated by the presence of multiple factor binding sites (84) (reviewed in Ref. 79). Thus, it is probably not fortuitous that p53 REs are composed of four half-sites and that p53 binds as a tetramer (85). The clustering of these sites and the cooperativity required between p53 monomers may have evolved to overcome the inhibitory nature of nucleosomes. This feature may also explain why p53 REs elements can be, and often are, located outside of the proximal promoter region where most cis-acting regulatory sequences are generally found.

In conclusion, we have characterized the chromatin structure of p53 REs and the core promoter regions for three p53-regulated genes. We report that the promoter regions of these genes contain an open chromatin configuration that is constitutive and unaffected by the presence or absence of p53. These findings establish a paradigm for p53 transactivation.

    ACKNOWLEDGEMENTS

We are deeply indebted to Drs. Ken Zaret and Anja-Katrin Bielinsky for advice and help with the DNase I hypersensitivity and chromatin immunoprecipitation assays, respectively. We thank Drs. Bielinsky and Julio Herrera for comments and criticisms of the manuscript.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant AI35763.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 612-624-5988; Fax: 612-624-0426; E-mail: hendr064@tc.umn.edu.

Published, JBC Papers in Press, December 9, 2002, DOI 10.1074/jbc.M204256200

    ABBREVIATIONS

The abbreviations used are: HAT, histone transacetylase; RE, response element; RT, reverse transcriptase; IR, ionizing radiation; Gy, gray; DHS, DNase I hypersensitive site; ChIP, chromatin immunoprecipitation; Ab, antibody; EKLF, erythroid Krueppel-like factor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Krebs, J. E., and Peterson, C. L. (2000) Crit. Rev. Eukaryotic Gene Expression 10, 1-12[Medline] [Order article via Infotrieve]
2. Mai, X., Chou, S., and Struhl, K. (2000) Mol. Cell. Biol. 20, 6668-6676[Abstract/Free Full Text]
3. Soutoglou, E., and Talianidis, I. (2002) Science 295, 1901-1904[Abstract/Free Full Text]
4. Felsenfeld, G., Boyes, J., Chung, J., Clark, D., and Studitsky, V. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9384-9388[Abstract/Free Full Text]
5. McAndrew, P. C., Svaren, J., Martin, S. R., Horz, W., and Goding, C. R. (1998) Mol. Cell. Biol. 18, 5818-5827[Abstract/Free Full Text]
6. Chen, C., and Yang, T. P. (2001) Mol. Cell. Biol. 21, 7682-7695[Abstract/Free Full Text]
7. Cosma, M. P., Panizza, S., and Nasmyth, K. (2001) Mol. Cell 7, 1213-1220[CrossRef][Medline] [Order article via Infotrieve]
8. Brown, R. C., Pattison, S., van Ree, J., Coghill, E., Perkins, A., Jane, S. M., and Cunningham, J. M. (2002) Mol. Cell. Biol. 22, 161-170[Abstract/Free Full Text]
9. Rougvie, A. E., and Lis, J. T. (1988) Cell 54, 795-804[Medline] [Order article via Infotrieve]
10. Graunke, D. M., Fornace, A. J., Jr., and Pieper, R. O. (1999) Nucleic Acids Res. 27, 3881-3890[Abstract/Free Full Text]
11. Albert, T., Wells, J., Funk, J. O., Pullner, A., Raschke, E. E., Stelzer, G., Meisterernst, M., Farnham, P. J., and Eick, D. (2001) J. Biol. Chem. 276, 20482-20490[Abstract/Free Full Text]
12. Fry, C. J., and Peterson, C. L. (2002) Science 295, 1847-1848[Free Full Text]
13. Hassan, A. H., Neely, K. E., Vignali, M., Reese, J. C., and Workman, J. L. (2001) Front. Biosci. 6, D1054-D1064[Medline] [Order article via Infotrieve]
14. Langst, G., and Becker, P. B. (2001) J. Cell Sci. 114, 2561-2568[Medline] [Order article via Infotrieve]
15. Roth, S. Y., Denu, J. M., and Allis, C. D. (2001) Annu. Rev. Biochem. 70, 81-120[CrossRef][Medline] [Order article via Infotrieve]
16. Bhaumik, S. R., and Green, M. R. (2001) Genes Dev. 15, 1935-1945[Abstract/Free Full Text]
17. Larschan, E., and Winston, F. (2001) Genes Dev. 15, 1946-1956[Abstract/Free Full Text]
18. Hoeijmakers, J. H. (2001) Nature 411, 366-374[CrossRef][Medline] [Order article via Infotrieve]
19. Norbury, C. J., and Hickson, I. D. (2001) Annu. Rev. Pharmacol. Toxicol. 41, 367-401[CrossRef][Medline] [Order article via Infotrieve]
20. Colman, M. S., Afshari, C. A., and Barrett, J. C. (2000) Mutat. Res. 462, 179-188[CrossRef][Medline] [Order article via Infotrieve]
21. Appella, E., and Anderson, C. W. (2001) Eur. J. Biochem. 268, 2764-2772[Abstract/Free Full Text]
22. Woods, D. B., and Vousden, K. H. (2001) Exp. Cell Res. 264, 56-66[CrossRef][Medline] [Order article via Infotrieve]
23. Szak, S. T., Mays, D., and Pietenpol, J. A. (2001) Mol. Cell. Biol. 21, 3375-3386[Abstract/Free Full Text]
24. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. (1992) Nat. Genet. 1, 45-49[Medline] [Order article via Infotrieve]
25. El-Deiry, W. S. (1998) Semin. Cancer Biol. 8, 345-357[CrossRef][Medline] [Order article via Infotrieve]
26. Hoffman, W. H., Biade, S., Zilfou, J. T., Chen, J., and Murphy, M. (2002) J. Biol. Chem. 277, 3247-3257[Abstract/Free Full Text]
27. Haupt, Y., Maya, R., Kazaz, A., and Oren, M. (1997) Nature 387, 296-299[CrossRef][Medline] [Order article via Infotrieve]
28. Kubbutat, M. H., Jones, S. N., and Vousden, K. H. (1997) Nature 387, 299-303[CrossRef][Medline] [Order article via Infotrieve]
29. Khosravi, R., Maya, R., Gottlieb, T., Oren, M., Shiloh, Y., and Shkedy, D. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 14973-14977[Abstract/Free Full Text]
30. Maya, R., Balass, M., Kim, S. T., Shkedy, D., Leal, J. F., Shifman, O., Moas, M., Buschmann, T., Ronai, Z., Shiloh, Y., Kastan, M. B., Katzir, E., and Oren, M. (2001) Genes Dev. 15, 1067-1077[Abstract/Free Full Text]
31. Liu, Y., and Kulesz-Martin, M. (2001) Carcinogenesis 22, 851-860[Abstract/Free Full Text]
32. Gu, W., and Roeder, R. G. (1997) Cell 90, 595-606[Medline] [Order article via Infotrieve]
33. Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., and Berger, S. L. (2001) Mol. Cell 8, 1243-1254[Medline] [Order article via Infotrieve]
34. Espinosa, J. M., and Emerson, B. M. (2001) Mol. Cell 8, 57-69[Medline] [Order article via Infotrieve]
35. Prives, C., and Manley, J. L. (2001) Cell 107, 815-818[CrossRef][Medline] [Order article via Infotrieve]
36. Waldman, T., Kinzler, K. W., and Vogelstein, B. (1995) Cancer Res. 55, 5187-5190[Abstract]
37. Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., and Vogelstein, B. (1998) Science 282, 1497-1501[Abstract/Free Full Text]
38. Frohman, M. A., Dush, M. K., and Martin, G. R. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8998-9002[Abstract]
39. Hecht, A., Strahl-Bolsinger, S., and Grunstein, M. (1996) Nature 383, 92-96[CrossRef][Medline] [Order article via Infotrieve]
40. Liu, J. K., Bergman, Y., and Zaret, K. S. (1988) Genes Dev. 2, 528-541[Abstract]
41. Braastad, C. D., Leguia, M., and Hendrickson, E. A. (2002) Nucleic Acids Res. 30, 1713-1724[Abstract/Free Full Text]
42. Parsons, R., Li, G.-M., Longley, M. J., Fang, W.-H., Papadopoulos, N., Jen, J., de la Chapelle, A., Kinzler, K. W., Vogelstein, B., and Modrich, P. (1993) Cell 75, 1227-1236[Medline] [Order article via Infotrieve]
43. Myung, K., He, D. M., Lee, S. E., and Hendrickson, E. A. (1997) EMBO J. 16, 3172-3184[Abstract/Free Full Text]
44. Gartel, A. L., and Tyner, A. L. (1999) Exp. Cell Res. 246, 280-289[CrossRef][Medline] [Order article via Infotrieve]
45. Prasad, G. L., Valverius, E. M., McDuffie, E., and Cooper, H. L. (1992) Cell Growth & Differ. 3, 507-513[Abstract]
46. Hermeking, H., Lengauer, C., Polyak, K., He, T.-C., Zhang, L., Thiagalingam, S., Kinzler, K. W., and Vogelstein, B. (1997) Mol. Cell 1, 3-11[Medline] [Order article via Infotrieve]
47. Ferguson, A. T., Evron, E., Umbricht, C. B., Pandita, T. K., Chan, T. A., Hermeking, H., Marks, J. R., Lambers, A. R., Futreal, P. A., Stampfer, M. R., and Sukumar, S. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 6049-6054[Abstract/Free Full Text]
48. Takimoto, R., and El-Deiry, W. S. (2000) Oncogene 19, 1735-1743[CrossRef][Medline] [Order article via Infotrieve]
49. Wu, C. (1989) Methods Enzymol. 170, 269-289[Medline] [Order article via Infotrieve]
50. Hecht, A., Strahl-Bolsinger, S., and Grunstein, M. (1999) Methods Mol. Biol. 119, 469-479[Medline] [Order article via Infotrieve]
51. Takenaka, I., Morin, F., Seizinger, B. R., and Kley, N. (1995) J. Biol. Chem. 270, 5405-5411[Abstract/Free Full Text]
52. Xiao, G., White, D., and Bargonetti, J. (1998) Oncogene 16, 1171-1181[CrossRef][Medline] [Order article via Infotrieve]
53. Lin, D., and Chinault, A. C. (1988) Somatic Cell Mol. Genet. 14, 261-272[Medline] [Order article via Infotrieve]
54. Litt, M. D., Hansen, R. S., Hornstra, I. K., Gartler, S. M., and Yang, T. P. (1997) J. Biol. Chem. 272, 14921-14926[Abstract/Free Full Text]
55. Nuez, B., Michalovich, D., Bygrave, A., Ploemacher, R., and Grosveld, F. (1995) Nature 375, 316-318[CrossRef][Medline] [Order article via Infotrieve]
56. Wijgerde, M., Gribnau, J., Trimborn, T., Nuez, B., Philipsen, S., Grosveld, F., and Fraser, P. (1996) Genes Dev. 10, 2894-2902[Abstract]
57. Pazin, M. J., Bhargava, P., Geiduschek, E. P., and Kadonaga, J. T. (1997) Science 276, 809-812[Abstract/Free Full Text]
58. Berk, A. J. (1999) Curr. Opin. Cell Biol. 11, 330-335[CrossRef][Medline] [Order article via Infotrieve]
59. Roberts, S. G. (2000) Cell. Mol. Life Sci. 57, 1149-1160[Medline] [Order article via Infotrieve]
60. Rogakou, E. P., Pilch, D. R., Orr, A. H., Ivanova, V. S., and Bonner, W. M. (1998) J. Biol. Chem. 273, 5858-5868[Abstract/Free Full Text]
61. Li, Y., DeFatta, R., Anthony, C., Sunavala, G., and De Benedetti, A. (2001) Oncogene 20, 726-738[CrossRef][Medline] [Order article via Infotrieve]
62. Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., and Appella, E. (1998) Genes Dev. 12, 2831-2841[Abstract/Free Full Text]
63. Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D., and Berger, S. L. (1999) Mol. Cell. Biol. 19, 1202-1209[Abstract/Free Full Text]
64. Ito, A., Lai, C. H., Zhao, X., Saito, S., Hamilton, M. H., Appella, E., and Yao, T. P. (2001) EMBO J. 20, 1331-1340[Abstract/Free Full Text]
65. Lu, Y., Ussery, G. D., Muncaster, M. M., Gallie, B. L., and Blanck, G. (1994) Oncogene 9, 1015-1019[Medline] [Order article via Infotrieve]
66. Zhu, X., Pattenden, S., and Bremner, R. (1999) Oncogene 18, 4940-4947[CrossRef][Medline] [Order article via Infotrieve]
67. Osborne, A., Zhang, H., Yang, W. M., Seto, E., and Blanck, G. (2001) Mol. Cell. Biol. 21, 6495-6506[Abstract/Free Full Text]
68. Lis, J., and Wu, C. (1993) Cell 74, 1-4[Medline] [Order article via Infotrieve]
69. Gonczy, P., Reith, W., Barras, E., Lisowska-Grospierre, B., Griscelli, C., Hadam, M. R., and Mach, B. (1989) Mol. Cell. Biol. 9, 296-302[Medline] [Order article via Infotrieve]
70. Lu, Q., Wallrath, L. L., Allan, B. D., Glaser, R. L., Lis, J. T., and Elgin, S. C. (1992) J. Mol. Biol. 225, 985-998[Medline] [Order article via Infotrieve]
71. Lu, Q., Wallrath, L. L., Granok, H., and Elgin, S. C. (1993) Mol. Cell. Biol. 13, 2802-2814[Abstract]
72. Brown, S. A., Imbalzano, A. N., and Kingston, R. E. (1996) Genes Dev. 10, 1479-1490[Abstract]
73. Plet, A., Eick, D., and Blanchard, J. M. (1995) Oncogene 10, 319-328[Medline] [Order article via Infotrieve]
74. Krumm, A., Meulia, T., Brunvand, M., and Groudine, M. (1992) Genes Dev. 6, 2201-2213[Abstract]
75. Strobl, L. J., and Eick, D. (1992) EMBO J. 11, 3307-3314[Abstract]
76. Kadonaga, J. T. (1990) J. Biol. Chem. 265, 2624-2631[Abstract/Free Full Text]
77. Pina, B., Bruggemeier, U., and Beato, M. (1990) Cell 60, 719-731[Medline] [Order article via Infotrieve]
78. Taylor, I. C., Workman, J. L., Schuetz, T. J., and Kingston, R. E. (1991) Genes Dev. 5, 1285-1298[Abstract]
79. Becker, P. B. (1994) Bioessays 16, 541-547[Medline] [Order article via Infotrieve]
80. Owen-Hughes, T., and Workman, J. L. (1994) Crit. Rev. Eukaryotic Gene Expression 4, 403-441[Medline] [Order article via Infotrieve]
81. McPherson, C. E., Shim, E. Y., Friedman, D. S., and Zaret, K. S. (1993) Cell 75, 387-398[Medline] [Order article via Infotrieve]
82. Tsukiyama, T., Becker, P. B., and Wu, C. (1994) Nature 367, 525-532[CrossRef][Medline] [Order article via Infotrieve]
83. Owen-Hughes, T., and Workman, J. L. (1996) EMBO J. 15, 4702-4712[Abstract]
84. Adams, C. C., and Workman, J. L. (1995) Mol. Cell. Biol. 15, 1405-1421[Abstract]
85. Cho, Y., Gorina, S., Jeffrey, P. D., and Pavletich, N. P. (1994) Science 265, 346-355[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.



This Article
Abstract
Full Text (PDF)
All Versions of this Article:
278/10/8261    most recent
M204256200v1
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Braastad, C. D.
Articles by Hendrickson, E. A.
Articles citing this Article
PubMed
PubMed Citation
Articles by Braastad, C. D.
Articles by Hendrickson, E. A.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.